2003
In Vitro and In Vivo Assays for the Proliferative and Vascular Permeabilization Activities of Vascular Endothelial Growth Factor (VEGF) and Its Receptor
Yano S, Herbst RS, Sone S. In Vitro and In Vivo Assays for the Proliferative and Vascular Permeabilization Activities of Vascular Endothelial Growth Factor (VEGF) and Its Receptor. Methods In Molecular Medicine 2003, 74: 391-398. PMID: 12415710, DOI: 10.1385/1-59259-323-2:391.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCapillary PermeabilityCell DivisionCells, CulturedEndothelial Growth FactorsEndothelium, VascularHumansImmunoglobulin GIn Vitro TechniquesIntercellular Signaling Peptides and ProteinsLymphokinesMaleMiceMice, Inbred C57BLMice, NudeReceptors, Vascular Endothelial Growth FactorRecombinant ProteinsTetrazolium SaltsThiazolesThymidineVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsNon-small cell lung cancerVascular endothelial growth factorLung cancerEarly-stage non-small cell lung cancerCell lung cancerNormal bronchial epitheliumEndothelial growth factorNew blood vesselsBronchial dysplasiaPoor prognosisPrimary tumorLung carcinogenesisMicrovascular densityBronchial epitheliumSolid tumorsBlood vesselsGrowth factorTumorsMetabolic demandsVivo assaysCancerEarly stagesCarcinomaPrognosisHyperplasia
2002
Phase I study of recombinant human endostatin in patients with advanced solid tumors.
Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O’Reilly M, Ellis LM, Pluda J, Hong WK, Abbruzzese JL. Phase I study of recombinant human endostatin in patients with advanced solid tumors. Journal Of Clinical Oncology 2002, 20: 3792-803. PMID: 12228199, DOI: 10.1200/jco.2002.11.061.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAngiogenesis InhibitorsCollagenCollagen Type XVIIIEndostatinsEndothelial Growth FactorsE-SelectinFemaleFibroblast Growth Factor 2Hematologic DiseasesHumansImmunoglobulinsInfusions, IntravenousLymphokinesMagnetic Resonance ImagingMaleMaximum Tolerated DoseMiddle AgedNeoplasmsPeptide FragmentsRecombinant ProteinsTime FactorsTissue DistributionVascular Cell Adhesion Molecule-1Vascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsRh-EndoConcentration-time curveRecombinant human endostatinSerum markersPreclinical modelsSolid tumorsHuman endostatinDose-limiting toxic effectAntitumor activityTwo-compartmental open modelAdvanced solid tumorsPhase I trialCentral line accessDose-finding trialMinor antitumor activityI trialIntravenous bolusSerum biomarkersSerum antibodiesPharmacokinetic dispositionAllergic reactionsPatientsPharmacokinetic profileDose levelsPhase ITargeted therapy in non-small-cell lung cancer.
Herbst RS. Targeted therapy in non-small-cell lung cancer. Oncology 2002, 16: 19-24. PMID: 12375797.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntibodies, MonoclonalAntineoplastic AgentsCarcinoma, Non-Small-Cell LungClinical Trials as TopicEndothelial Growth FactorsErbB ReceptorsHumansIntercellular Signaling Peptides and ProteinsLung NeoplasmsLymphokinesProtein Kinase CVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsCell lung cancerLung cancerSuch new agentsNew agentsVascular endothelial growth factor inhibitorsPlatinum-based combination therapyEGFR tyrosine kinase inhibitorsGrowth factor receptor inhibitorsNew biologic therapiesGrowth factor inhibitorsEpithelial growth factor receptor inhibitorTyrosine kinase inhibitorsSpecific biologic pathwaysDevelopment of agentsSignal transduction inhibitorsMaintenance therapyBiologic therapyCytotoxic chemotherapyStages of treatmentFactor inhibitorsCombination therapyTargeted therapyReceptor inhibitorsRadiation therapyClinical investigationAssessment of Antiangiogenic Effect Using 99mTc-EC-Endostatin
Yang DJ, Kim KD, Schechter NR, Yu DF, Wu P, Azhdarinia A, Roach JS, Kalimi SK, Ozaki K, Fogler WE, Bryant JL, Herbst R, Abbruzzes J, Kim EE, Podoloff DA. Assessment of Antiangiogenic Effect Using 99mTc-EC-Endostatin. Cancer Biotherapy & Radiopharmaceuticals 2002, 17: 233-246. PMID: 12030117, DOI: 10.1089/108497802753773856.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisCollagenCysteineEndostatinsEndothelial Growth FactorsFemaleFibroblast Growth Factor 2In Situ Nick-End LabelingIntercellular Signaling Peptides and ProteinsInterleukin-8LymphokinesMammary Neoplasms, ExperimentalNeovascularization, PathologicPaclitaxelPeptide FragmentsRadionuclide ImagingRatsRats, Inbred F344TechnetiumTumor Cells, CulturedVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsTumor-bearing ratsAnti-angiogenesis therapyTreatment responseTumor uptakeTUNEL assayAnti-angiogenic treatment responseTumor vascular densityIL-8 expressionTumor-bearing animal modelsCount density ratiosCell viabilityPrognostic indicatorMicrovessel densityVascular densityAnimal modelsEndostatin therapyAntiangiogenic effectsMetastatic potentialTherapyUptake doseCellular uptake assaysEndostatinTissue distributionRatsEthylenedicysteineAngiogenesis inhibitors in clinical development for lung cancer
Herbst RS, Hidalgo M, Pierson AS, Holden SN, Bergen M, Eckhardt SG. Angiogenesis inhibitors in clinical development for lung cancer. Seminars In Oncology 2002, 29: 66-77. PMID: 11894016, DOI: 10.1053/sonc.2002.31527.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntineoplastic Combined Chemotherapy ProtocolsClinical Trials as TopicDisease ProgressionEndothelial Growth FactorsEndpoint DeterminationEnzyme InhibitorsHumansLung NeoplasmsLymphokinesMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesNeovascularization, PathologicTreatment OutcomeVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsAngiogenesis inhibitorsLung cancerClinical trialsClinical developmentPhase II trialLong-term administrationPlatinum-based therapyEarly clinical trialsReceptor-targeted agentsPrimary endpointAdvanced diseaseII trialMetastatic diseaseAdjunctive therapyProcess of angiogenesisCancer patientsField of angiogenesisEfficacious dosesClinical evaluationTumor regressionNovel agentsAntiangiogenic agentsTherapeutic targetDependence of tumorsTumor angiogenesis
2000
Production of Experimental Malignant Pleural Effusions Is Dependent on Invasion of the Pleura and Expression of Vascular Endothelial Growth Factor/Vascular Permeability Factor by Human Lung Cancer Cells
Yano S, Shinohara H, Herbst R, Kuniyasu H, Bucana C, Ellis L, Fidler I. Production of Experimental Malignant Pleural Effusions Is Dependent on Invasion of the Pleura and Expression of Vascular Endothelial Growth Factor/Vascular Permeability Factor by Human Lung Cancer Cells. American Journal Of Pathology 2000, 157: 1893-1903. PMID: 11106562, PMCID: PMC1885766, DOI: 10.1016/s0002-9440(10)64828-6.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAnimalsCapillary PermeabilityCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCytokinesEndothelial Growth FactorsHumansLungLung NeoplasmsLymphokinesMatrix MetalloproteinasesMiceMice, NudeNeoplasm InvasivenessNeoplasm TransplantationOligonucleotides, AntisensePleuraPleural EffusionTissue Inhibitor of MetalloproteinasesTransfectionTumor Cells, CulturedUrokinase-Type Plasminogen ActivatorVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsExpression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis.
Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Davis DW, McConkey DJ, Fidler IJ. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Research 2000, 60: 4959-67. PMID: 10987313.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBrain NeoplasmsCell DivisionCytokinesDNA, AntisenseEndothelial Growth FactorsHumansLymphokinesMaleMiceMice, NudeNeoplasm TransplantationNeovascularization, PathologicRNA, MessengerTransfectionTumor Cells, CulturedVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsBrain metastasesCell carcinomaHuman lung squamous carcinoma cellsLung squamous carcinoma cellsLung squamous cell carcinomaExperimental brain metastasesParenchymal brain metastasesSquamous cell carcinomaInternal carotid arteryVascular endothelial growth factorRenal cell carcinomaEndothelial growth factorImportant therapeutic targetInhibition of VEGFSquamous carcinoma cellsLung adenocarcinoma cellsCancer cell linesDifferent human cancer cell linesCarotid arteryNude miceTherapeutic targetKM12SM cellsMetastasisHuman cancer cell linesVEGF expressionTreatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clinical Cancer Research 2000, 6: 957-65. PMID: 10741721.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAngiogenesis InhibitorsAnimalsCapillary PermeabilityCell DivisionCell LineEndothelial Growth FactorsEndothelium, VascularGene Expression RegulationHumansImmunohistochemistryIn Situ HybridizationLung NeoplasmsLymphokinesMaleMiceMice, Inbred BALB CMice, NudeNeoplasm TransplantationNeovascularization, PathologicPhosphorylationPhthalazinesPleural Effusion, MalignantPyridinesReceptor Protein-Tyrosine KinasesReceptors, Growth FactorReceptors, Vascular Endothelial Growth FactorTransplantation, HeterologousTumor Cells, CulturedVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsMalignant pleural effusionReceptor tyrosine kinase inhibitorsPleural effusionPTK 787Human dermal microvascular endothelial cellsTyrosine kinase inhibitorsPC14PE6 cellsDermal microvascular endothelial cellsMicrovascular endothelial cellsVEGF/VPFOral treatmentLung lesionsGrowth factor receptor tyrosine kinase inhibitorsAdvanced human lung cancerPlatelet-derived growth factor receptor tyrosine kinase inhibitorVEGF/VPF proteinEndothelial cellsKinase inhibitorsVascular endothelial growth factor/vascular permeability factorHuman lung cancerNude mouse modelHuman lung adenocarcinomaHuman lung adenocarcinoma cellsVascular permeability factorHuman lung carcinoma cells